SpringerLink
Log in

Amyloid imaging in depression: a predictor of Alzheimer’s disease?

  • Editorial Commentary
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Thies W, Bleiler L. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 2013;9(2):208–45.

    Article  PubMed  Google Scholar 

  2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.

    Article  CAS  PubMed  Google Scholar 

  3. Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:257–62.

    Article  PubMed  PubMed Central  Google Scholar 

  4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.

    Article  CAS  PubMed  Google Scholar 

  7. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.

    Article  CAS  PubMed  Google Scholar 

  8. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain. 2007;130:2837–44.

    Article  PubMed  Google Scholar 

  9. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131:1630–45.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–83.

    Article  CAS  PubMed  Google Scholar 

  11. Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50(5):818–22.

    Article  CAS  PubMed  Google Scholar 

  12. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355(25):2652–63.

    Article  CAS  PubMed  Google Scholar 

  13. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7.

    Article  PubMed  Google Scholar 

  14. Juréus A, Swahn B-M, Sandell J, Jeppsson F, Johnson AE, Johnström P, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010;114:784–94.

    Article  PubMed  Google Scholar 

  15. Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880–6.

    Article  CAS  PubMed  Google Scholar 

  16. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.

    Article  PubMed  Google Scholar 

  17. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39:983–9.

    Article  CAS  PubMed  Google Scholar 

  18. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83(9):923–6.

    Article  PubMed  Google Scholar 

  19. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26:8–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lin K-J, Hsu W-C, Hsiao I-T, Wey S-P, ** L-W, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent–a pilot study. Nucl Med Biol. 2010;37:497–508.

    Article  CAS  PubMed  Google Scholar 

  23. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404–11.

    Article  PubMed  Google Scholar 

  24. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469–75.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73:754–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Någren K, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011;76:1085–90.

    Article  CAS  PubMed  Google Scholar 

  27. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79:1636–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med. 2013;54:476–90.

    Article  CAS  PubMed  Google Scholar 

  29. Cortes-Blanco A, Prieto-Yerro C, Martinez-Lazaro R, Zamora J, Jiménez-Huete A, Haberkamp M, et al. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval. Alzheimer’s Dement 2014 in press.

  30. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71:903–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79:1331–8.

    Article  CAS  PubMed  Google Scholar 

  32. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol. 2009;41:1261–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837–44.

    Article  CAS  PubMed  Google Scholar 

  34. Wu K-Y, Hsiao I-T, Chen C-S, Chen C-H, Hsieh C-J, Wai Y-Y, et al. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on (18)F-florbetapir (AV-45/Amyvid) positron emission tomography. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2627-0.

  35. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202:329–35.

    Article  PubMed  Google Scholar 

  36. Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MMB. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology. 2008;70:1258–64.

    Article  CAS  PubMed  Google Scholar 

  37. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530–8.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Smith DF, Jakobsen S. Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol. 2009;19:611–28.

    Article  CAS  PubMed  Google Scholar 

  39. Savitz JB, Drevets WC. Neuroreceptor imaging in depression. Neurobiol Dis. 2013;52:49–65.

    Article  CAS  PubMed  Google Scholar 

  40. Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA, et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord. 2008;22:261–8.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lavretsky H, Siddarth P, Kepe V, Ercoli LM, Miller KJ, Burggren AC, et al. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatr. 2009;17:493–502.

    Article  Google Scholar 

  42. Madsen K, Hasselbalch BJ, Frederiksen KS, Haahr ME, Gade A, Law I, et al. Lack of association between prior depressive episodes and cerebral [11C]PiB binding. Neurobiol Aging. 2012;33:2334–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, Hospital de Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

    Valle Camacho

  2. Neurology Department, Institut d’Investigacions Biomediques Sant Pau, Hospital de Sant Pau, Barcelona, Spain

    Alberto LLeó

  3. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

    Alberto LLeó

Authors
  1. Valle Camacho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto LLeó
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valle Camacho.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Camacho, V., LLeó, A. Amyloid imaging in depression: a predictor of Alzheimer’s disease?. Eur J Nucl Med Mol Imaging 41, 711–713 (2014). https://doi.org/10.1007/s00259-014-2741-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-014-2741-7

Search

Navigation